Oramed Pharmaceuticals Inc.
Clinical-stage company developing oral drug delivery for injectable medications.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Manufacturing
Description
Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-04 01:33 |
Form S-3
|
English | 228.9 KB | ||
| 2021-02-04 01:33 |
Form S-3
|
English | 36.0 KB | ||
| 2021-01-28 11:16 |
Oramed Issues Letter to Shareholders
|
English | 230.0 KB | ||
| 2021-01-28 11:16 |
Oramed Issues Letter to Shareholders
|
English | 36.0 KB | ||
| 2021-01-21 16:53 |
Doses Patients Across Multiple Sites in Phase 3 Oral Insulin
Study
|
English | 131.5 KB | ||
| 2021-01-21 16:53 |
Doses Patients Across Multiple Sites in Phase 3 Oral Insulin
Study
|
English | 36.0 KB | ||
| 2021-01-16 21:28 |
FORM 10-Q-For the quarterly period ended November 30, 2020
|
English | 318.9 KB | ||
| 2021-01-16 21:28 |
FORM 10-Q-For the quarterly period ended November 30, 2020
|
English | 36.0 KB | ||
| 2020-12-23 16:24 |
Reports Positive First in Human Data from Oral Leptin Study
|
English | 196.5 KB | ||
| 2020-12-23 16:24 |
Reports Positive First in Human Data from Oral Leptin Study
|
English | 36.0 KB | ||
| 2020-12-02 16:57 |
screened the first patients in a trial of ORMD-0801 for the treatment of NASH
|
English | 83.8 KB | ||
| 2020-12-02 16:57 |
screened the first patients in a trial of ORMD-0801 for the treatment of NASH
|
English | 36.0 KB | ||
| 2020-12-02 01:37 |
Form 8K - Equity Distribution Agreement, dated December 1, 2020
|
English | 368.8 KB | ||
| 2020-12-02 01:37 |
Form 8K - Equity Distribution Agreement, dated December 1, 2020
|
English | 36.0 KB | ||
| 2020-12-02 01:29 |
Form 424B5 - PROSPECTUS SUPPLEMENT Dated December 1, 2020
|
English | 269.4 KB |
Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oramed Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
